XOMA Royalty Stock Quote XOMA - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

27.09

Bid

26.55

Ask

29.07

Volume

31,384

26.14 Day's Range 28.64

13.48 52 Week Range 30.36

Market Cap

317.074M

Previous Close

28.19

Open

28.64

Last Trade

102

27.09

(priorref)

Last Trade Time

16:02:10

Financial Volume

$ 846,874

VWAP

26.9842

Average Volume (3m)

22,522

Shares Outstanding

11,704,467

Dividend Yield

PE Ratio

-7.70

Earnings Per Share (EPS)

-3.49

Revenue

4.76M

Net Profit

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.xoma.com

Headquarters

Wilmington, Delaware, USA

Founded

XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMA. The last closing price for XOMA Royalty was $28.19. Over the last year, XOMA Royalty shares have traded in a share price range of $ 13.48 to $ 30.36.

XOMA Royalty currently has 11,704,467 shares outstanding. The market capitalization of XOMA Royalty is $329.95 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -7.70.

Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder XOMA Royalty is entitled to receive a mid-single digit royalty on MIPLYFFA™ sales and up to $52.6...

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following...

XOMA Royalty to Present at Upcoming Investor Conferences in September

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at...

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the...

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from...

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the...

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and...

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.89	-6.52173913043	28.98	29.9	26.855	26443	28.60408879	CS
4	-1.49	-5.21343596921	28.58	29.9	25.95	23478	28.34864132	CS
12	3.68	15.7197778727	23.41	30.36	22.7	22522	27.55336594	CS
26	2.02	8.05743917032	25.07	30.36	21.27	17846	26.45353328	CS
52	11.45	73.2097186701	15.64	30.36	13.48	22223	21.99893442	CS
156	2.44	9.8985801217	24.65	32.085	13.48	29157	20.69514426	CS
260	6.99	34.776119403	20.1	46.32	13.48	35978	24.20175034	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MSSMaison Solutions Inc	$ 1.77 (147.55%)	9.64M
LGHLWLion Group Holding Ltd	$ 0.0084 (31.25%)	36.26k
EDUCEducational Development Corporation	$ 2.63 (30.85%)	2.28M
HSCSHeart Test Laboratories Inc	$ 3.75 (27.55%)	274.93k
LBRDALiberty Broadband Corporation	$ 73.00 (21.93%)	82.92k
BIVIBioVie Inc	$ 1.30 (-53.57%)	246.47k
XPONExpion360 Inc	$ 0.1044 (-10.77%)	4.96M
PRSOPeraso Inc	$ 1.40 (-9.97%)	338.68k
EJHE Home Household Service Holdings Ltd	$ 0.092 (-9.89%)	2.14M
JFBRJeffs Brands Ltd	$ 0.349 (-8.16%)	82.2k
LUXHLuxUrban Hotels Inc	$ 0.11 (19.18%)	11.88M
MSSMaison Solutions Inc	$ 1.77 (147.55%)	9.64M
BLUEbluebird bio Inc	$ 0.5266 (7.71%)	8.39M
CMCSAComcast Corporation	$ 40.73 (0.00%)	6.29M
CSCOCisco Systems Inc	$ 52.29 (0.19%)	5.81M